{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:26:41Z","timestamp":1778884001670,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National\u00a0Key\u00a0R&D\u00a0Program\u00a0of\u00a0China","award":["2017YFC0907704"],"award-info":[{"award-number":["2017YFC0907704"]}]},{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","award":["81801202"],"award-info":[{"award-number":["81801202"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2018SZ0388"],"award-info":[{"award-number":["2018SZ0388"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00415-019-09649-7","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T16:02:51Z","timestamp":1574870571000},"page":"913-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study"],"prefix":"10.1007","volume":"267","author":[{"given":"Ziyan","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-6947","authenticated-orcid":false,"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"9649_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"9649_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"9649_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/1352458512472748","volume":"19","author":"SM Kim","year":"2013","unstructured":"Kim SM, Waters P, Woodhall M et al (2013) Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler 19:1060\u20131067","journal-title":"Mult Scler"},{"key":"9649_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","volume":"21","author":"L Pandit","year":"2015","unstructured":"Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21:845\u2013853","journal-title":"Mult Scler"},{"key":"9649_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","volume":"89","author":"H Houzen","year":"2017","unstructured":"Houzen H, Kondo K, Niino M et al (2017) Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 89:1995\u20132001","journal-title":"Neurology"},{"key":"9649_CR6","doi-asserted-by":"publisher","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","volume":"91","author":"V Papp","year":"2018","unstructured":"Papp V, Illes Z, Magyari M et al (2018) Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 91:e2265\u2013e2275","journal-title":"Neurology"},{"key":"9649_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","volume":"88","author":"W Bukhari","year":"2017","unstructured":"Bukhari W, Prain KM, Waters P et al (2017) Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 88:632\u2013638","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9649_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","volume":"17","author":"A Bruscolini","year":"2018","unstructured":"Bruscolini A, Sacchetti M, La Cava M et al (2018) Diagnosis and management of neuromyelitis optica spectrum disorders\u2014an update. Autoimmun Rev 17:195\u2013200","journal-title":"Autoimmun Rev"},{"key":"9649_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY, Kim SH, Hyun JW et al (2014) Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 71:1372\u20131378","journal-title":"JAMA Neurol"},{"key":"9649_CR10","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264:2003\u20132009","journal-title":"J Neurol"},{"key":"9649_CR11","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","volume":"9","author":"Q Huang","year":"2018","unstructured":"Huang Q, Wang J, Zhou Y et al (2018) Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol 9:2066","journal-title":"Front Immunol"},{"issue":"8","key":"9649_CR12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/1352458518776584","volume":"25","author":"DB Bichuetti","year":"2018","unstructured":"Bichuetti DB, Perin M, Souza NA, Oliveira E (2018) Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler 25(8):1150\u20131161","journal-title":"Mult Scler"},{"key":"9649_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324\u2013330","journal-title":"JAMA Neurol"},{"key":"9649_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann JP, Krumbholz M, Friede T et al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 88:639\u2013647","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9649_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849","journal-title":"Brain"},{"key":"9649_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1177\/1352458516687403","volume":"23","author":"SH Kim","year":"2017","unstructured":"Kim SH, Hyun JW, Joung A et al (2017) Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. Mult Scler 23:1902\u20131908","journal-title":"Mult Scler"},{"key":"9649_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE (1998) Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219\u20131220","journal-title":"Neurology"},{"key":"9649_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128\u20131133","journal-title":"Arch Neurol"},{"key":"9649_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659\u2013666","journal-title":"Neurology"},{"key":"9649_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","volume":"24","author":"H Chen","year":"2017","unstructured":"Chen H, Qiu W, Zhang Q et al (2017) Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 24:219\u2013226","journal-title":"Eur J Neurol"},{"key":"9649_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"9649_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","volume":"291","author":"S Jarius","year":"2010","unstructured":"Jarius S, Probst C, Borowski K et al (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52\u201356","journal-title":"J Neurol Sci"},{"key":"9649_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","volume":"90","author":"S Mariotto","year":"2019","unstructured":"Mariotto S, Ferrari S, Gastaldi M et al (2019) Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J Neurol Neurosurg Psychiatry 90:1293\u20131296","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9649_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH et al (2016) Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 22:329\u2013339","journal-title":"Mult Scler"},{"key":"9649_CR25","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"SH Kim","year":"2018","unstructured":"Kim SH, Mealy MA, Levy M et al (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91:e2089\u2013e2099","journal-title":"Neurology"},{"key":"9649_CR26","unstructured":"Cameron DP, Jonas K, Paul Z, Ben K, Andrew FG, Abdeali JK, Rendeiro AF (2019) CamDavidsonPilon\/lifelines: v0.22.10 (Version v0.22.10). Zenodo. doi: 10.5281\/zenodo.3533087."},{"key":"9649_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Kitley J, Luppe S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20:1533\u20131540","journal-title":"Mult Scler"},{"issue":"5","key":"9649_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"42","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 42(5):1310\u20131323","journal-title":"Brain"},{"key":"9649_CR29","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00415-017-8606-9","volume":"264","author":"H Kang","year":"2017","unstructured":"Kang H, Chen T, Li H et al (2017) Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol 264:2130\u20132140","journal-title":"J Neurol"},{"key":"9649_CR30","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1352458513515085","volume":"20","author":"N Collongues","year":"2014","unstructured":"Collongues N, Marignier R, Jacob A et al (2014) Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20:1086\u20131094","journal-title":"Mult Scler"},{"key":"9649_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","volume":"80","author":"P Cabre","year":"2009","unstructured":"Cabre P, Gonzalez-Quevedo A, Bonnan M et al (2009) Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 80:1162\u20131164","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09649-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:24:25Z","timestamp":1606350265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09649-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["9649"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09649-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"28 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest, including relevant financial interests, activities, relationships, or affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Medical Ethics Committee of West China Hospital, Sichuan University and was performed in accordance with the ethical standards of the Declaration of Helsinki (approval number: 2018-29). All participants provided informed consent prior to their inclusion in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}